Paris, February 24, 2010 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), will present its first results showing that meganuclease engineering can improve the features of a parental cell line used to produce biodrugs. The presentation will be made at the Cell Line Development and Engineering Conference in Prague on March 3, 2010. “This constitutes further proof of the efficiency of meganucleases in genome customization,” explained Luc Selig, Sales and Marketing Director at Cellectis bioresearch. “Our engineering of biodrug producing cells reveals the potential and the very high specificity of meganucleases”.
Meganucleases are innovative tools that enable targeted modification to DNA to obtain precise and stable modifications in the genome. Cellectis bioresearch’s current products enable targeted gene integration. The results to be presented in Prague broaden the potential range of applications of the technology by demonstrating the ability of a specific meganuclease to knock-out an endogenous gene.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional study.
More information at www.cellectis-bioresearch.com
About Cellectis S.A.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over €70 million in funding since inception.
More information at www.cellectis.com
